Biodexa provides update on progression free and overall survival in phase 1 study of mtx110 in recurrent glioblastoma

October 4, 2024 biodexa provides update on progression free and overall survival in phase 1 study of mtx110 in recurrent glioblastoma cohort a data on overall survival compare favorably with published survival rates results build on mtx110's performance in two phase 1 studies in diffuse midline glioma biodexa pharmaceuticals plc (“biodexa” or “the company”), (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces an update in respect of its open label phase 1 study of mtx110 in recurrent glioblastoma. in october 2023, the company announced completed recruitment of four patients into cohort a of its phase 1 study of mtx110 (also known as magic-g1 study)(nct 05324501) in patients with recurrent glioblastoma (rgbm).
BDRX Ratings Summary
BDRX Quant Ranking